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within the CB1 receptor
Introduction
Ø Functional antagonists of the cannabinoid receptor 1 (CB1)
receptor are considered to have great potential in obesity
management.
ØMost neutral antagonists and inverse agonists bind to the main
(orthosteric) site of CB1, and are CNS-active, exhibiting adverse
neuropsychiatric effects.
Ø In contrast, negative allosteric modulators (NAMs) block CB1
signaling by binding at a site that is topologically distinct from the
orthosteric site.
ØNAMs are highly selective. They exhibit a ceiling effect, probe
dependence and biased signaling, making them less liable to
elicit CNS-mediated adverse effects.
ØORG27569, an intrinsic inverse agonist and negative allosteric
modulator (NAM) of CB1, increases the binding affinity of agonist
CP55940.
Ø In this study, we applied computational methods to identify the
binding site of ORG27569, amidst contradictory reports in the
literature (Fig. 1).
ØCB1 receptor models were built using each of the four X-ray
crystal structures4-6 of CB1 as a template, with the N-terminus
added on through our computational modeling, in order to be able
to include the reported C98–C107 disulfide bridge.
ØCP55940 was docked into each of the four CB1 receptor models
using the Glide7 Standard Precision (SP) protocol of Schrödinger.
ØSiteMap8, Schrödinger was used to identify the top-ranked
potential binding sites in the CB1–CP55940 complexes.
ØORG27569 was docked into all the pockets identified using
SiteMap.
ØA 50 ns molecular dynamics simulation was performed on the
5U09 model of the CB1 receptor bound to CP55940, using the
OPLS3 force field.
ØA SiteMap analysis was run on frames extracted every 0.5 ns
from the trajectory.
ØMolecular docking studies of ORG27569 were performed on six
predominant site clusters obtained from the trajectory using the
Glide SP protocol, InducedFit docking and Prime9 free energy
calculations.
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Fig. 1. (Left) CB1 
model created from 
the inactive-state X-
ray CB1 crystal 
structure, 5U09, 
with the orthosteric 
site highlighted in 
blue and previously 
predicted allosteric 
sites1-3 in orange. 
(Right) CB1 NAM, 
ORG27569, and 
CB1/CB2 agonist, 
CP55940.
Ø To identify the binding pose of CP55940 within the CB1 X-ray
crystal structures.
Ø To identify potential allosteric sites in the active-state and
inactive-state complexes of the CB1 receptor bound to CP55940.
Ø To identify the preferred binding site of ORG27569 within an
inactive-state CB1–CP55940 complex.
Ø To determine the binding site of ORG27569 will aid rational
design of novel NAMs of the CB1 receptor.
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ØEnhanced MD simulations (such as
metadynamics) of the
ORG27569−CP55940−CB1 complex using data
from previously-reported mutagenesis studies.
ØAssessment of the mechanism by which
ORG27569 interferes with CP55940-induced
CB1 activation.
Ø The orientation of CP55940, which aligned well
with native poses of the co-crystallized ligands
within the experimental active-state CB1
structures, validated its docking pose within the
inactive-state models.
ØBinding site analysis and subsequent molecular
docking with ORG27569 on the rigid receptor
models did not provide a consensus binding
site for ORG27569.
ØBinding site analysis performed on the flexible
receptor model, using a conformational
ensemble of the protein, provided more
information about the probability of finding a
particular site at any time.
Ø The best docking site for ORG27569 was found
at an intracellular site on CB1, near helices 2, 6
and 7.Ø The docking orientation of CP55940 in all four models of CB1 was similar (Fig.
2).
ØDocked poses of CP55940 obtained in the active-state CB1 X-ray structures
were highly similar to the binding poses of the co-crystallized ligands, with an
RMSD <1 Å for common heavy atoms.
ØSiteMap analysis revealed multiple allosteric sites within the CP55940-bound
CB1 complexes (Fig. 3).
ØRigid receptor docking within the allosteric sites identified by SiteMap did not
provide a consensus docking site for ORG27569 across all structures (Fig. 4).
Fig. 3. Maps of identified allosteric binding sites (each site’s surface in different color) for the 
CP55940-bound complex of the CB1 receptor, using X-ray structures of the inactive-state (A) 
5TGZ and (B) 5U09; and active-state (C) 5XR8 and (D) 5XRA. CP55940 (C magenta; non-
polar hydrogen atoms are not shown, for clarity) is shown in the orthosteric site. 
Fig. 6. ORG27569 (C orange) and CP55940 (C cyan) 
within the 5U09-based CB1 structure. Hydrogen bonds are 
shown using black dashed lines. Non-polar hydrogen 
atoms are not shown for clarity.
Fig. 5. Site points of six predominant site clusters 
(SC) in the 5U09-based CB1–CP55940 complex 
following a 50 ns MD simulation. 
ØSince the SiteMap and docking protocols
consider a rigid receptor conformation
that is most suited for docking of small
molecules that are very similar to the
native ligand, we performed an MD
simulation of the CB1–CP55940 complex
to generate multiple receptor
conformations and performed binding site
analysis on them.
ØOf thirty site clusters obtained from the
MD simulations, six site clusters were
present in at least 40 of the frames
processed (Fig. 5).
ØMolecular docking studies of ORG27569
within the site clusters revealed that site
cluster 3 was the most favored (Table 1).
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Fig. 2. Docked CP55940 (C purple) overlaid with the co-crystallized ligand 
within each of the four X-ray crystal structure-based CB1 models.
SC1
SC8
SC5
SC6
SC3
SC13
Site 
Cluster
Glide 
Gscore a IFD Score 
a Prime Free 
Energy a
1 −6.190 −549.22 −50.00
3 −9.740 −556.08 −86.82
5 −6.542 −489.49 −66.50
6 −8.439 −495.44 −76.66
8 −7.862 −495.47 −65.08
13 −6.862 −493.61 −64.92
Table 1. The docking performance of 
ORG27569 within the predominant site 
clusters obtained from the CP55940-
bound complex of CB1.
R214Y153
D403
D338
Y397
TM I
5TGZ
TM I
5U095XR85XRA
Fig. 4. Most favorable docking sites for ORG27569 (C orange) within the rigid CP55940-bound 
CB1 complexes. CP55940 (C magenta). Non-polar hydrogen atoms are not shown for clarity.
ØORG27569 docked best at an
intracellular site near helices 2, 6 and 7
(SC3) within CB1 (Fig. 6).
Ø Two hydrogen bond interactions were
observed with Y153 and D403,
similar to interactions found with the
β2AR intracellular antagonist, Cmpd-
15PA10.
Ø The close proximity of ORG27569 to
the canonical ionic lock residues,
R214 and D338, may account for
disruption of CB1 signaling. a Units: kcal/mol
